The non-selective alpha-adrenergic antagonists block both alpha-1 (α1) and alpha-2 (α2) receptor subtypes, distinguishing them from the selective agents that constitute most of contemporary clinical practice. Their clinical roles are narrow but irreplaceable: phenoxybenzamine for the preoperative management of pheochromocytoma, and phentolamine for hypertensive emergencies and diagnostic testing in catecholamine excess states. The critical pharmacological distinction between these two drugs is the nature of their receptor binding.
Phenoxybenzamine: Irreversible Blockade. Phenoxybenzamine is a haloalkylamine that forms a stable covalent bond with alpha-adrenergic receptors through an aziridinium intermediate, producing irreversible, non-competitive receptor alkylation. Because the blockade is covalent, it cannot be overcome by increasing concentrations of agonist, and the duration of effect depends entirely on new receptor synthesis, which takes several days. The pharmacokinetic profile reflects this mechanism: onset of action after oral dosing is slow (onset 1 to 2 hours, peak 4 to 6 hours), but the duration of a single dose extends 24 to 48 hours or longer. Oral bioavailability is variable (approximately 20 to 30%), so doses must be titrated carefully. The drug is lipophilic and widely distributed, accumulating in adipose tissue and fat, which contributes to its prolonged biological effect even after the drug is cleared from plasma.1
Cardiovascular Effects of Phenoxybenzamine. Blockade of α1 receptors on arterioles and veins reduces peripheral vascular resistance and causes venodilation, lowering both systolic and diastolic blood pressure. Because α2 autoreceptors on presynaptic sympathetic terminals are simultaneously blocked, the normal feedback inhibition of norepinephrine (NE) release is removed. Presynaptic α2 autoreceptors normally suppress NE release when ambient NE concentration rises; with α2 blockade, norepinephrine is released without restraint, producing a reflex tachycardia that is more pronounced than with selective α1 blockers. This unopposed β1-mediated tachycardia is both a side effect and a pharmacological marker of adequate α blockade when titrating phenoxybenzamine in pheochromocytoma management. The hypotensive effect is orthostatic (greatest on standing), and patients characteristically experience significant postural hypotension, nasal congestion from mucosal vasodilation, and miosis from α1 blockade of the iris dilator muscle.12
Phentolamine: Competitive, Reversible Blockade. Phentolamine is a non-selective α1 and α2 antagonist that competes reversibly with catecholamines for receptor binding sites. Unlike phenoxybenzamine, phentolamine's blockade can be overcome by sufficiently high concentrations of agonist, and its effects terminate as the drug is eliminated. The plasma half-life after intravenous (IV) administration is approximately 19 minutes, making it highly titratable for acute hemodynamic management. Phentolamine is administered parenterally (IV or intramuscular (IM)) because oral bioavailability is negligible due to extensive first-pass hepatic metabolism. The drug also blocks serotonin receptors and inhibits neuronal and extraneuronal uptake of catecholamines at high concentrations, contributing to its overall sympatholytic effect. Because it also blocks presynaptic α2 receptors, it produces the same reflex tachycardia as phenoxybenzamine through uninhibited NE release.12
Clinical Applications of Phentolamine. Phentolamine's primary clinical roles exploit its rapid onset and short duration. In hypertensive emergencies caused by catecholamine excess (pheochromocytoma crisis, tyramine-induced hypertension in patients taking monoamine oxidase inhibitors (MAOIs), clonidine withdrawal, or cocaine-induced hypertensive crisis), phentolamine 2.5 to 5 mg IV produces a rapid, titratable reduction in blood pressure lasting 15 to 30 minutes per dose. It is the drug of choice for hypertensive emergencies caused by catecholamine excess because it directly antagonizes the α1 vasopressor effect responsible for the blood pressure elevation. A second important application is the treatment of norepinephrine extravasation: phentolamine 5 to 10 mg diluted in normal saline, infiltrated subcutaneously around the extravasation site, competitively blocks α1 receptors in the skin and subcutaneous tissues, reversing the vasoconstriction that causes ischemic necrosis, as previously described in Module 02. Phentolamine was historically used as a diagnostic provocative test for pheochromocytoma (the phentolamine test), but this has been replaced by biochemical assays for urinary catecholamines, metanephrines, and plasma free metanephrines.23
Phenoxybenzamine: irreversible covalent α1/α2 blockade; oral; slow onset; 24–48 hr duration; used for preoperative pheochromocytoma preparation (days to weeks of titration). Phentolamine: reversible competitive α1/α2 blockade; IV/IM only; onset 1–2 min; duration 15–30 min; used for acute hypertensive emergencies and NE extravasation. Both produce reflex tachycardia from α2 blockade (disinhibited NE release).
The selective alpha-1 antagonists were developed to provide the antihypertensive benefits of alpha blockade without the pronounced reflex tachycardia caused by non-selective agents. By preserving α2 autoreceptor feedback, these drugs allow the presynaptic sympathetic terminal to sense and respond to increased ambient catecholamines, limiting the reflex increase in norepinephrine (NE) release and thereby attenuating the reflex tachycardia. This pharmacological refinement made selective α1 blockade clinically viable for long-term antihypertensive therapy and for management of benign prostatic hyperplasia (BPH).
Mechanism of Selective Alpha-1 Blockade. Prazosin, terazosin, and doxazosin are quinazoline derivatives that competitively and reversibly block α1A, α1B, and α1D receptor subtypes. Alpha-1A receptors mediate smooth muscle contraction in the bladder neck, internal urethral sphincter, and prostate stroma; α1B receptors mediate vascular smooth muscle contraction in blood vessels; α1D receptors are present in the aorta, iliac arteries, and lower urinary tract. Blockade of vascular α1 receptors reduces arteriolar resistance and venous return, lowering blood pressure. Blockade of α1A and α1D receptors in the lower urinary tract reduces smooth muscle tone in the prostate capsule, bladder neck, and urethra, improving urinary flow in men with BPH. Because presynaptic α2 autoreceptors are preserved, NE release is still subject to feedback inhibition, and reflex tachycardia is markedly attenuated compared with non-selective agents.4
First-Dose Phenomenon. A clinically important adverse effect shared by all selective α1 blockers is the first-dose phenomenon: a profound, syncopal episode of orthostatic hypotension occurring within 30 to 90 minutes of the first dose or after a significant dose increase. The mechanism involves sudden loss of venous and arteriolar tone without a compensatory increase in heart rate or cardiac output (because α2 autoreceptors remain intact and feedback-inhibit the reflex catecholamine release). The first-dose phenomenon is most severe in volume-depleted patients, elderly individuals with impaired cardiovascular reflexes, and patients simultaneously receiving other antihypertensives or phosphodiesterase type 5 (PDE5) inhibitors. To minimize risk, the initial dose should be taken at bedtime while supine; patients should be warned of the risk of syncope on first standing; and the starting dose should be the lowest available (prazosin 1 mg, terazosin 1 mg, doxazosin 1 mg). Dose escalation should be gradual with reassessment of standing blood pressure at each increment.45
Absorption, Distribution, Metabolism, and Excretion (ADME) Differences. The three drugs differ in pharmacokinetics in ways that influence dosing schedules and clinical selection. Prazosin has the shortest half-life (approximately 2 to 3 hours) and requires twice- or three-times-daily dosing; peak plasma concentration occurs at 1 to 3 hours after oral administration. Terazosin has an intermediate half-life of approximately 12 hours, allowing once-daily dosing; it undergoes primarily hepatic metabolism by oxidative demethylation and glucuronidation. Doxazosin has the longest half-life among the three (approximately 22 hours), is the most convenient for once-daily dosing, and is available in an extended-release formulation that further smooths plasma concentration profiles and reduces the first-dose phenomenon. All three are highly protein-bound (greater than 95%), primarily metabolized by the liver (by the cytochrome P450 3A4 isoform (CYP3A4) for doxazosin; primarily non-CYP pathways for prazosin and terazosin), and have moderate to high oral bioavailability (50 to 65% for prazosin; approximately 90% for terazosin and doxazosin).45
Antihypertensive Use and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. All three drugs are approved for hypertension and were widely used as first-line antihypertensives before the publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) trial in 2002. In ALLHAT, doxazosin was randomized against chlorthalidone (a thiazide-type diuretic) as initial antihypertensive therapy in high-risk patients. The doxazosin arm was terminated early due to a significantly higher rate of combined cardiovascular disease events, specifically a doubling of congestive heart failure (CHF) admissions compared with chlorthalidone. This finding shifted the position of selective α1 blockers from first-line antihypertensives to adjunctive agents used when first-line options are contraindicated or insufficient. They remain useful for hypertension in men with coexisting BPH (addressing both conditions simultaneously), in patients with refractory hypertension on multiple agents, and in patients with hypertriglyceridemia (selective α1 blockers improve lipid profiles slightly by reducing triglycerides and increasing high-density lipoprotein (HDL) cholesterol).56
Always administer the first dose at bedtime while supine. Start at the lowest available dose (prazosin 1 mg, terazosin 1 mg, doxazosin 1 mg). Hold PDE5 inhibitors (sildenafil, tadalafil, vardenafil) for at least 4 hours before or after the first dose and after any dose increase — their combination with α1 blockers substantially increases the risk of severe hypotension. Increase doses gradually (every 1–2 weeks) with standing blood pressure checks. Most severe in volume-depleted and elderly patients.
The development of tamsulosin and silodosin marked a further refinement of receptor subtype selectivity within the alpha-1 blocker class. By preferentially targeting α1A receptors, which predominate in the prostate, bladder neck, and urethra, over α1B receptors, which mediate vascular smooth muscle contraction, these agents achieve meaningful urological benefit with substantially less systemic hypotension than the non-subtype-selective alpha-1 blockers. This vascular sparing makes them the dominant pharmacological treatment for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) in current practice.
Receptor Subtype Selectivity. The alpha-1 receptor family comprises three pharmacologically distinct subtypes: α1A (predominant in prostate, urethra, bladder neck, and iris), α1B (predominant in blood vessels, particularly capacitance vessels), and α1D (present in aorta, iliac arteries, and detrusor). The clinical rationale for α1A-selective blockade is that BPH-related urinary obstruction is largely mediated by α1A receptor-driven smooth muscle contraction in the prostate capsule and bladder outlet. Tamsulosin has an α1A to α1B selectivity ratio of approximately 10:1; silodosin has an even higher selectivity ratio of approximately 162:1. This selective α1A preference means that vascular α1B-mediated smooth muscle contraction is relatively preserved, reducing the degree of systemic vasoconstriction relief and therefore producing less orthostatic hypotension than non-subtype-selective α1 blockers. However, α1A receptors in the iris dilator muscle are also blocked, which has an important surgical implication described below.7
Absorption, Distribution, Metabolism, and Excretion (ADME) and Clinical Dosing. Tamsulosin is administered as a modified-release capsule (0.4 mg once daily, taken 30 minutes after the same meal each day) to reduce peak plasma concentration and further attenuate any cardiovascular effects. Oral bioavailability is approximately 90% under fed conditions (reduced under fasting conditions). The plasma half-life is 9 to 13 hours in extensive metabolizers and up to 14 to 15 hours in poor metabolizers; the drug is primarily metabolized by CYP3A4 (the cytochrome P450 3A4 isoform) and CYP2D6 (the cytochrome P450 2D6 isoform). Silodosin is administered as 8 mg once daily with meals; it has an oral bioavailability of approximately 32%, is metabolized by CYP3A4 and uridine 5'-diphospho-glucuronosyltransferase (UGT2B7), and has a half-life of approximately 11 hours. Both drugs are highly protein-bound (greater than 94%) and are excreted primarily in urine as metabolites. A clinically relevant difference is that silodosin produces a higher rate of retrograde ejaculation (approximately 28%) compared with tamsulosin (approximately 4 to 11%) because α1A receptors in the bladder neck and internal sphincter mediate seminal emission; more complete α1A blockade prevents bladder neck closure during ejaculation, redirecting semen into the bladder rather than the urethra.78
Intraoperative Floppy Iris Syndrome. Intraoperative floppy iris syndrome (IFIS) is a well-established complication of cataract surgery that occurs disproportionately in patients taking α1A-selective antagonists, particularly tamsulosin. The syndrome is characterized by a triad of intraoperative findings: progressive iris prolapse through the phacoemulsification incision, iris billowing and floppiness in response to irrigation currents, and intraoperative miosis despite standard mydriatic agents. The mechanism is α1A blockade of the iris dilator muscle, which normally contracts in response to sympathetic stimulation to maintain pupil dilation. With α1A blockade, the dilator is pharmacologically paralyzed and cannot be adequately antagonized by topical atropine or phenylephrine administered preoperatively, because the receptor coupling is blocked rather than the muscarinic constriction being the limiting factor. IFIS increases the risk of posterior capsular rupture, vitreous loss, and other serious intraoperative complications. The risk persists even if tamsulosin was discontinued months or years before surgery, because the α1A receptor expression in the iris dilator does not recover to full responsiveness. Ophthalmologists must be informed of current or prior tamsulosin and silodosin use before cataract surgery so that modified surgical techniques (pupil expansion rings, modified irrigation, smaller incisions) can be planned prospectively.8
All patients taking or having ever taken tamsulosin or silodosin must inform their ophthalmologist before cataract surgery. The risk persists indefinitely after drug discontinuation. Preoperative mydriatic agents are ineffective because α1A receptor blockade prevents iris dilator response, not muscarinic-mediated constriction. Modified surgical techniques are required. Prescribers should document α1A blocker use prominently in the patient record and counsel patients to disclose this history before any ophthalmic procedure.
Pheochromocytoma is a catecholamine-secreting tumor of the adrenal medulla chromaffin cells; paraganglioma is its extra-adrenal counterpart arising from sympathetic ganglia. Both present a pharmacological challenge because uncontrolled catecholamine release during surgical manipulation without adequate preoperative alpha blockade can cause life-threatening hypertensive crises, arrhythmias, and hemodynamic instability. The pharmacological preparation of these patients for surgery represents the most critical clinical application of alpha-adrenergic antagonists.
Biochemical Diagnosis. The biochemical diagnosis of pheochromocytoma relies on measurement of catecholamines and their metabolites, specifically metanephrines (metanephrine and normetanephrine), which are produced by continuous intratumoral catechol-O-methyltransferase (COMT)-mediated catabolism within the chromaffin cells. Because this intratumoral metabolism is constitutive and independent of episodic catecholamine secretion, plasma free metanephrines have higher sensitivity (approximately 97 to 99%) for pheochromocytoma detection than catecholamine measurements, which are elevated only during or shortly after a secretory episode.9 The Endocrine Society guideline recommends plasma free metanephrines or 24-hour urinary fractionated metanephrines and catecholamines as the preferred biochemical tests. Elevated values should lead to anatomic localization with cross-sectional imaging (computed tomography (CT) or magnetic resonance imaging (MRI)), followed by functional imaging (fluorodeoxyglucose (FDG) positron emission tomography (PET) or meta-iodobenzylguanidine (MIBG) scan) when multisite or hereditary disease is suspected.3
Preoperative Alpha Blockade: The Role of Phenoxybenzamine. Alpha-adrenergic blockade is the cornerstone of preoperative preparation because it prevents the catastrophic hypertensive responses triggered by anesthetic induction, tumor manipulation, and ligation of tumor blood supply. The irreversible covalent mechanism of phenoxybenzamine provides several pharmacological advantages in this context: the sustained, non-competitive blockade cannot be overcome by the massive catecholamine surges that occur during surgical manipulation; the prolonged duration means consistent blood pressure control without sharp peaks or troughs; and the gradual titration over 1 to 2 weeks allows volume repletion as the vasoconstriction that chronically depletes plasma volume is progressively reversed. The standard protocol begins at 10 mg twice daily and is increased every 2 to 3 days by 10 to 20 mg increments to a target of 20 to 40 mg twice to three times daily. Adequacy of blockade is assessed by blood pressure normalization (less than 130/80 mmHg with less than 10 mmHg orthostatic drop on standing), resolution of symptoms, and development of reflex tachycardia and nasal congestion (indicators that peripheral α blockade has been achieved). During titration patients are encouraged to consume a high-sodium diet and liberal fluid intake to correct the chronic volume depletion that is a consistent feature of prolonged catecholamine excess.29
Beta-Blockade Sequencing. The reflex tachycardia and cardiac arrhythmias associated with pheochromocytoma (and with phenoxybenzamine-induced NE disinhibition) may require beta-blockade, but the sequencing is pharmacologically critical: beta-blockade must never be initiated before adequate alpha blockade is established. The reason is that catecholamine excess states are driven by both α and β receptor activation; in patients with active catecholamine excess, β2-mediated vasodilation in skeletal muscle vasculature provides a partial counterbalance to α1-mediated vasoconstriction. If beta-blockade is administered first, this β2-mediated vasodilation is eliminated while α1-mediated vasoconstriction remains unopposed, potentially triggering severe hypertension and end-organ damage. Once alpha blockade is established and blood pressure is controlled, a beta-blocker (typically propranolol or atenolol) may be added to control persistent tachycardia or arrhythmias. The commonly used mnemonic for this sequencing is: "alpha first, then beta." Calcium channel blockers (particularly nicardipine and amlodipine) are useful adjuncts and in some centers serve as the primary or alternative antihypertensive for pheochromocytoma preoperative preparation.2910
Step 1: Establish α blockade with phenoxybenzamine (10 mg BID, titrate over 1–2 weeks). Step 2: Add β-blocker (propranolol, atenolol) ONLY after adequate α blockade is confirmed. Step 3: High-sodium diet and liberal fluids to correct volume depletion. Never initiate β-blockade before α-blockade in catecholamine excess — unopposed α1 vasoconstriction may cause hypertensive crisis. Goals: BP <130/80 mmHg; no orthostatic drop >10 mmHg; heart rate (HR) 60–80 bpm supine; nasal congestion and postural hypotension confirming peripheral blockade.
Yohimbine is the prototypical selective alpha-2 (α2) receptor antagonist, derived from the bark of the West African tree Pausinystalia yohimbe. Its pharmacological mechanism is the mirror image of the alpha-2 agonists discussed in Module 03: whereas clonidine and dexmedetomidine reduce sympathetic outflow by activating presynaptic α2 autoreceptors, yohimbine blocks those same autoreceptors, disinhibiting norepinephrine (NE) release and increasing central and peripheral sympathetic tone. This mechanism produces predictable cardiovascular, neurological, and metabolic effects that have been exploited in clinical research and, more recently, promoted (often without strong evidence) in over-the-counter preparations for weight loss and sexual dysfunction.
Mechanism of Alpha-2 Antagonism. Alpha-2 receptors exist in two pharmacologically relevant locations: presynaptically on noradrenergic nerve terminals (autoreceptors that provide feedback inhibition of NE release) and postsynaptically in the central nervous system (CNS), peripheral blood vessels, and pancreatic islet cells. Yohimbine blocks both locations but its most clinically consequential effect is presynaptic α2 autoreceptor blockade. When α2 autoreceptors are blocked, the normal mechanism that senses rising synaptic NE and curtails further release is disabled, resulting in uninhibited, continued NE exocytosis. The resulting increase in synaptic NE activates postsynaptic α1 and β1 receptors on the heart and blood vessels, increasing heart rate, blood pressure, and cardiac output. In the CNS, blockade of α2 receptors in the brainstem and locus coeruleus increases noradrenergic neurotransmission, producing anxiety, restlessness, and sympathomimetic arousal. Yohimbine also has moderate affinity for serotonin (5-HT1A and 5-HT1B) receptors and dopamine type-2 (D2) receptors, contributing to its complex neurological effects.11
Cardiovascular Effects. The cardiovascular profile of yohimbine is the opposite of clonidine: whereas clonidine lowers blood pressure and heart rate via central α2 agonism, yohimbine raises both via α2 antagonism and consequent NE disinhibition. Blood pressure and heart rate increases are dose-dependent and are exaggerated in patients with autonomic dysfunction (such as those with essential hypertension, post-traumatic stress disorder (PTSD), or panic disorder) who have altered central adrenergic regulation. In patients with orthostatic hypotension from autonomic failure, yohimbine has been investigated as a pharmacological treatment because the increase in sympathetic NE release can modestly increase standing blood pressure; however, its narrow therapeutic window and high adverse effect burden have limited its clinical adoption. The drug is contraindicated in patients with hypertension, cardiac disease, renal disease, and anxiety disorders.1112
Clinical and Research Applications. Yohimbine has well-established use as a research probe for exploring the role of central noradrenergic systems in psychiatry. It reliably produces anxiety, panic, and PTSD symptom re-emergence in susceptible individuals, making it a validated pharmacological challenge model for studying these conditions. In psychopharmacology research, the yohimbine challenge test is used to assess noradrenergic dysregulation in PTSD, panic disorder, and major depressive disorder. Clinical applications outside research are limited. Yohimbine was previously approved as a treatment for male erectile dysfunction before the advent of phosphodiesterase type 5 (PDE5) inhibitors; its modest benefit (approximately 34 to 43% improvement in erectile function versus placebo in early trials) is attributable to increased NE-mediated vascular tone and possibly enhanced central arousal. It is no longer recommended for this indication given the superior efficacy and tolerability of PDE5 inhibitors. As an over-the-counter weight loss supplement, yohimbine's evidence base is insufficient to justify its use, and the US Food and Drug Administration (FDA) does not recognize it as effective for this indication.1112
Common: anxiety, palpitations, tachycardia, hypertension, tremor, diaphoresis, nausea, headache. Serious: hypertensive crisis (particularly in MAOI-treated patients or in those with pheochromocytoma), panic attacks, mania precipitation in bipolar disorder. Contraindicated in: hypertension, cardiac disease, renal insufficiency, anxiety disorders, PTSD, psychiatric disorders requiring monoamine-based treatment. Not recommended for erectile dysfunction (PDE5 inhibitors preferred) or weight loss (insufficient evidence).
The alpha-adrenergic antagonists interact with other vasoactive drugs in pharmacodynamically predictable ways, primarily through additive or antagonistic effects on blood pressure and vascular tone. The most clinically consequential interactions involve phosphodiesterase type 5 (PDE5) inhibitors, other antihypertensives, sympathomimetics, and the specific context of anesthetic management in patients on chronic alpha blockade.
PDE5 Inhibitors and Alpha-1 Blockers. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil, avanafil) lower blood pressure by increasing cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, producing systemic and pulmonary vasodilation. Alpha-1 blockers lower blood pressure by blocking α1-mediated vascular smooth muscle contraction. Both drug classes act on the vasculature by independent mechanisms, and their combination produces additive vasodilatory effects that can cause symptomatic, severe hypotension. This interaction is most pronounced with the first dose of the alpha-1 blocker or with dose escalation, and is attenuated once stable alpha blockade is established. Current prescribing guidelines specify a minimum interval of 4 to 6 hours between administration of a non-uroselective α1 blocker and a PDE5 inhibitor. Tamsulosin 0.4 mg has a more favorable interaction profile with PDE5 inhibitors (studied with sildenafil and tadalafil) than non-uroselective agents, though caution is still required.513
Additive Antihypertensive Effects. Alpha-1 blockers have additive blood pressure-lowering effects with all other classes of antihypertensives: diuretics, calcium channel blockers (CCBs), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and beta-blockers. These combinations are often intentional in patients with resistant hypertension requiring multiple agents. However, the combination of an α1 blocker with a thiazide diuretic or loop diuretic in a volume-depleted patient can precipitate profound orthostatic hypotension; patients should be counseled that diuretic use increases their risk of postural dizziness on alpha blockade. The combination of α1 blockers with beta-blockers in pheochromocytoma preoperative management is intentional and sequenced (alpha first), as described in Section 4. Outside of that specific context, beta-blocker co-administration attenuates the reflex tachycardia caused by α1 blockade, which may be clinically useful.46
Sympathomimetics and Alpha-Antagonist Reversal. The vasopressor response to α1 agonists (epinephrine, norepinephrine, phenylephrine) is diminished in patients with established alpha blockade. In the specific context of a patient who has received phenoxybenzamine or a high-dose α1 blocker and then develops severe hypotension (such as intraoperatively), standard vasopressor doses may be ineffective. This is the basis for the well-known "epinephrine reversal" phenomenon in pharmacology: when a full dose of epinephrine is given to a patient with complete α blockade, the α1-mediated vasopressor component is blocked while the β2-mediated vasodilatory component remains; the net result is a paradoxical fall in blood pressure (or insufficient pressor response) rather than the expected rise. In anesthetic practice, patients on phenoxybenzamine for pheochromocytoma preoperative preparation should have phenylephrine, norepinephrine, and vasopressin available intraoperatively because large doses may be needed to overcome the established α blockade during the period of post-resection hypotension.2
Prazosin in Post-Traumatic Stress Disorder. Beyond its antihypertensive and urological applications, prazosin has an established evidence base as a pharmacological treatment for trauma-related nightmares and sleep disturbance in post-traumatic stress disorder (PTSD). The mechanism is believed to involve blockade of central α1 receptors in brain regions that mediate arousal and nightmares (amygdala, prefrontal cortex), reducing the hyperadrenergic state associated with PTSD sleep disturbance. Multiple randomized controlled trials and a Veterans Affairs cooperative study have demonstrated reduction in nightmare frequency and improved sleep quality with prazosin 1 to 15 mg at bedtime. This application represents a distinct clinical role for a drug primarily developed for cardiovascular indications, and prazosin for PTSD is considered a standard off-label use endorsed by multiple psychiatric treatment guidelines.14
PDE5 inhibitors + α1 blockers: additive vasodilation; severe hypotension risk; 4–6 hour separation required; tamsulosin has most favorable profile. Other antihypertensives + α1 blockers: additive hypotension; diuretics increase orthostatic risk. Sympathomimetics in α-blocked patients: reduced pressor response; epinephrine reversal with complete α blockade; use norepinephrine or vasopressin for intraoperative hypotension in phenoxybenzamine-prepared patients. Yohimbine + MAOIs or hypertensive medications: hypertensive crisis risk. Prazosin + CNS depressants at bedtime: additive hypotension and sedation; titrate carefully when using for PTSD nightmares.
Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018:191-224.
Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92(11):4069-4079.
doi:10.1210/jc.2007-1720Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942.
doi:10.1210/jc.2014-1498Chapple CR. Pharmacotherapy for benign prostatic hyperplasia — the potential for alpha1-adrenoceptor subtype-specific blockade. Br J Urol. 1998;81(Suppl 1):34-47.
doi:10.1046/j.1464-410x.1998.0810s1034.xKirby RS. The clinical pharmacology of novel alpha1-adrenoceptor-selective antagonists. Br J Clin Pharmacol. 1998;45(2):101-108.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997.
doi:10.1001/jama.288.23.2981Roehrborn CG. Efficacy of alpha-adrenoceptor blockers in the treatment of benign prostatic hyperplasia. Br J Urol. 1998;81(Suppl 1):14-23.
Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31(4):664-673.
doi:10.1016/j.jcrs.2005.02.027Eisenhofer G, Lenders JW, Siegert G, et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med. 1999;340(24):1872-1879.
doi:10.1056/NEJM199906173402404Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24(4):539-553.
doi:10.1210/er.2002-0013Goldberg MR, Robertson D. Yohimbine: a pharmacological probe for study of the alpha2-adrenoreceptor. Pharmacol Rev. 1983;35(3):143-180.
Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998;159(2):433-436.
doi:10.1016/S0022-5347(01)63942-9McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793-1803.
doi:10.1016/j.juro.2011.01.074Raskind MA, Peskind ER, Chow B, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med. 2018;378(6):507-517.
doi:10.1056/NEJMoa1507598